Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

Fig. 1

A Kaplan-Meier estimates of overall survival in patients (n = 87) treated with carboplatin/paclitaxel plus bevacizumab (experimental group). Patients are dichotomised by their median average expression of c-MET/VEGFR-2 into c-MET/VEGFR-2HIGH (n = 42) and c-MET/VEGFR-2LOW (n = 45) groups. The median OS was 39.3 months for c-MET/VEGFR-2HIGH and >60 months c-MET/VEGFR-2LOW (HR 2.00, P = 0.03). B Kaplan-Meier estimates of overall survival in patients (n=90) treated with carboplatin/paclitaxel (control group). Patients are dichotomised by their median average expression of c-MET/VEGFR-2 into c-MET/VEGFR-2HIGH (n = 46) and c-MET/VEGFR-2LOW (n = 44) groups. Both groups had a median OS > 60 months.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us